MedTrace Logo

The Influence of Timing of Cabergoline Initiation on Prevention of OHSS

NCT02620605 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2018-04-10

No results posted yet for this study

Summary

Study the effect of early cabergoline administration in prevention of occurrence or decreasing the severity of OHSS in patients undergoing intra cytoplasmic sperm injection.And its effect on oocyte maturation,fertilization and pregnancy rate..

Conditions

  • Ovarian Hyperstimulation Syndrome

Interventions

DRUG

Late Cabergoline 0.5mg

Cabergoline 0.5mg will be administrated once daily at day of HCG trigger and continued for 8days

DRUG

Early Cabergoline 0.5mg

Cabergoline 0.5mg will be administrated once daily when E2 is more than 4000pg/ml and /or more than 18 follicles of 11mm diameter or more are encountered at any day of the controlled ovarian hyper-stimulation and before HCG trigger to be continued for 8days after HCG trigger.

Sponsors & Collaborators

  • Mona M Shaban

    lead OTHER

Principal Investigators

  • Mona M Shaban, MD

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-20
Primary Completion
2018-12-31
Completion
2019-04-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02620605 on ClinicalTrials.gov